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The blood-brain barrier (BBB) supplies brain tissues with nutrients, filters harmful
compounds from the brain back to the bloodstream, and plays a key role in iron
homeostasis in the human brain. Disruptions of the BBB are associated with several
neurodegenerative conditions including Parkinson’s disease (PD). Oxidative stress, iron
deposition and mitochondrial impaired function are considered as risk factors for
degeneration of the central nervous system. Heme oxygenase (HMOX) degrades heme
ring to biliverdin, free ferrous iron and carbon monoxide being the rate-limiting activity in
heme catabolism. The isoform HMOX1 is highly inducible in response to reactive oxygen
species, which induce an increase in BBB permeability and impair its pathophysiology.
Consequently, an over- expression of this enzyme may contribute to the marked iron
deposition found in PD. We analyzed the HMOX1 SNPs rs2071746, rs2071747, and
rs9282702, a microsatellite (GT)n polymorphism and copy number variations in 691
patients suffering from PD and 766 healthy control individuals. Copy number variations
in the HMOX1 gene exist, but these do not seem to be associated with PD risk. In
contrast two polymorphisms that modify the transcriptional activity of the gene, namely a
VNTR (GT)n and the SNP rs2071746, are strongly associated with PD risk, particularly with
the classic PD phenotype and with early onset of the disease. This study indicates that
HMOX1 gene variants are associated to the risk of developing some forms of PD, thus
adding new information that supports association of HMOX gene variations with PD risk.
Keywords: Parkinson’s disease, Heme oxygenase, polymorphisms, copy number variations, biomarkers,
blood-brain barrier, iron homeostasis
INTRODUCTION
The blood-brain barrier (BBB) supplies brain tissues with nutri-
ents, filters harmful compounds from the brain back to the
bloodstream, and plays a key role in iron homeostasis in
human brain. Disruptions of the BBB are associated with several
neurodegenerative diseases including Parkinson’s disease (PD).
Oxidative stress, iron deposition and mitochondrial impaired
function are considered as risk factors for degeneration of the
central nervous system (Schipper, 2004; Alonso-Navarro et al.,
2008). In addition, it has been postulated that BBB inflam-
mation may be related to PD risk by causing over-activation
of microglia, increased production of cytokines and release
of reactive oxygen species (Whitton, 2007), and the possibil-
ity that PD may be related to blood borne toxins could be
the cause of these neurodegenerative disorders if the integrity
of BBB is compromised (for a recent review, see Kim et al.,
2012).
PD is one of the most common neurodegenerative movement
disorders; current demographic trends indicate a lifetime risk
approaching 4% (Schapira, 2013). The mean age of onset is 70
years, although 4% of patients develop early-onset, before the
age of 50 (Schrag and Schott, 2006). This disease is character-
ized by rest tremors, rigidity, slowness of movement and postural
imbalance. The primary pathologic abnormalities are the loss
of the pigmented cells of the substancia nigra pars compacta,
and the dopaminergic neurons of the striatum, which decreases
in dopamine levels (Lu’o’ng and Nguyen, 2012). Other central
and peripheral dopaminergic and non-dopaminergic systems are
also involved. Regarding the pathogenesis of neurodegeneration
in PD, patients show increased levels of oxidized lipids and a
decrease in levels of glutathione (Zeevalk et al., 2008; Obeso et al.,
2010; Schapira, 2012). In these patients, concentration of phos-
pholipids and polyunsaturated free fatty acids, which are highly
susceptible to oxidants, is decreased, whereas malondialdehyde, a
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marker of lipid oxidation, is increased (Dexter et al., 1989; Zhou
et al., 2008). Several studies have suggested the occurrence of
genetic factors related to PD risk, but so far no major genetic
risk factors have been identified, and it is widely accepted that PD
is likely to be related to genetic plus environmental interaction
(Schrag and Schott, 2006; Obeso et al., 2010; Trinh and Farrer,
2013; Alonso-Navarro et al., 2014) and that further genetic asso-
ciation studies based on solid functional mechanisms related to
the pathogenesis of the disease are required.
A relevant feature of the development of PD is abnormal
iron deposition in the substantia nigra of PD patients, as has
been demonstrated both in post-mortem studies (Sofic et al.,
1988) and in in vivo studies (Hochstrasser et al., 2004; Berg
and Hochstrasser, 2006). Some consequences of elevated nigral
iron levels are well known. The intranigral administration of
iron produces selective dopaminergic neuronal loss and elic-
its parkinsonian symptoms (Youdim, 2003). Alteration of iron
homeostasis, dysfunction in molecules involved in sequestering
excess iron, as well as ageing, are considered as possible causes
of elevated iron deposition. BBB protects the brain against cir-
culating iron, however the specific mechanisms involved in the
regulation of iron release and transport that lead to iron accu-
mulation in aging and neurological disorders such as PD, are
not completely understood. The involvement of dysregulation of
brain iron homeostasis in PD has been recently revised (Weinreb
et al., 2013). It was suggested that alterations in brain vasculariza-
tion in certain areas may cause high levels of iron (Faucheux et al.,
1999).
Heme oxygenase (HMOX) enzyme activity degrades heme
ring to biliverdin, free ferrous iron and carbon monoxide being
the rate-limiting activity in heme catabolism (Ryter and Tyrrell,
2000). Two HMOX isoforms have been described in the mam-
malian central nervous system: HMOX1 is present in neurons and
neuroglia (Benjamini and Hochberg, 1995), and it is inducible or
repressible by pro-oxidant and other microenvironment stimuli
(Kinobe et al., 2006; Loboda et al., 2008). HMOX2 is ubiqui-
tously and constitutively expressed throughout the mammalian
neuraxis, predominantly in substantia nigra, septum and hip-
pocampus (Verma et al., 1993; Maines, 1997). A third isoform
unique to rats, designated as HMOX3, exists (Scapagnini et al.,
2002). The role of single nucleotide polymorphisms (SNPs) in the
HMOX2 gene in patients with PD has been reported, theHMOX2
SNP rs2270363 being associated with PD risk (Ayuso et al., 2011).
In contrast, little is known about the role of genetic variations
in the HMOX1 gene in PD, and controversial findings justify the
analysis of this gene in a large sample population (Funke et al.,
2009; Infante et al., 2010). HMOX1 is a plausible candidate gene
for PD risk because immunoreactive HMOX1 has been identified
in dopaminergic neurons of PD patients (Castellani et al., 1996;
Schipper, 1998). In addition, neurotoxins, cytokines and nitric
oxide are considered as inducers of astroglial HMOX1 expres-
sion (Rieder et al., 2004; Schipper, 2004). Moreover, under stress
conditions in astroglia, HMOX1 promotes mitochondrial seques-
tration of non-transferrin iron and may contribute to the patho-
logical iron deposition described in PD (Schipper et al., 2009).
In this study we analyze common variations and copy number
variations in the HMOX1 gene, selected according to their allelic
frequencies and putative functional effect on enzyme activity, in a
large sample of patients with PD and healthy controls.
METHODS
Subjects were recruited from several centers in Spain. The study
group was composed of 691 PD patients and 766 healthy con-
trols, which were included in the study after obtaining informed
consent. From these, 460 patients with PD and 459 control indi-
viduals were recruited from the Clínica Universidad de Navarra
(Pamplona, Spain). In addition, 231 patients with PD were
recruited from the Hospital de La Princesa (Madrid, Spain)
and 307 controls were included from the latter hospital and
from the Infanta Cristina University Hospital (Badajoz, Spain).
Most participants had been included in previous studies by our
group (Agundez et al., 2008a; Garcia-Martin et al., 2008; Ayuso
et al., 2011; Lorenzo-Betancor et al., 2011; Jimenez-Jimenez et al.,
2014). All the participants were Caucasian Spanish individuals as
stated in the self-report. All consecutive patients diagnosed by
consultant neurologists according to the criteria recommended
by Hughes et al. (1992) were requested to participate and all
of them agreed to do so. Selection criteria for patients with PD
included bradykinesia and at least one of the following symptoms:
rigidity, resting tremor, postural instability, a positive response
to dopaminergic therapy, and the absence of atypical features or
other causes of parkinsonism (Hughes et al., 1992). From the total
of patients, only 36 of the 691 patients with PD had a positive
family history of the disease and monogenic forms of PD were
excluded. Patients were divided in three groups according to dif-
ferent phenotypes: tremor-dominant patients with PD (TD-PD),
classical phenotype patients with PD (C-PD), or akinetic-rigid
patients with PD (AR-PD) when such information was available
(Lorenzo-Betancor et al., 2011). As the classification of motor PD
phenotype subgroups can be arbitrary, we considered those indi-
viduals with rest tremor as dominant and an initial feature of
their disease to have a TD-PD. AR-PD phenotype was considered
for those individuals with predominant bradykinesia or signs of
rigidity, but mild or no tremor at rest. The patients with compara-
ble severity of tremor, rigidity, and bradykinesia were considered
patients with C-PD. A medical examination was performed to
identify individuals in good health. The study was approved by
the ethics committees of the institutions involved in the study.
For all participants, genomic DNA was obtained from peripheral
leukocytes and purified according to standard procedures. Table 1
summarizes the demographic data of the subgroups analyzed in
the study.
Four polymorphisms in the HMOX1 gene, located in
chromosome 22q12, were selected for genotyping on the
basis of putative functional effects as well as expected allele
frequency in Caucasian individuals as reported in public
databases (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.
cgi?showRare=on&chooseRs=all&go=Go&locusId=3162). These
polymorphisms included a variable number tandem repeat
(VNTR), consisting of alternating the purine-pyrimidine
sequence (GT)n which has the potential to acquire the Z-DNA
conformation, a structure which is thermodynamically unfavor-
able compared with the B-DNA structure. This formation has
been described as a factor that negatively affects transcriptional
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Table 1 | Demographic data of the sample analyzed in this study.
Group Controls (n = 766) PD
Entire PD (n = 691) TD-PD (n = 30) C-PD (n = 328) AR-PD (n = 94) Unclassifiable PDa
(n = 239)
Age, y, mean (SD) 64.67 (14.28) 67.09 (10.62) 69,51 (8.09) 67.06 (10.68) 66.00 (10.79) 67.32 (11.76)
Age range, y 17–102 22–95 49–87 22–95 39–87 41–88
AAO, y, mean (SD) NA 59.57 (12.61) 62.82 (8.13) 57.55 (11.58) 56.81 (11.59) 63.51 (13.65)
AAO range, y NA 17–90 46–76 17–84 34–84 18–90
Female % 45.7% 42.6% 43.3% 36.8% 42.5% 50.2%
PD, Parkinson’s disease; y, years; AAO, age at onset; SD, standard deviation; NA, not available; TD-PD, tremor-dominant Parkinson’s disease; C-PD, classical PD
phenotype; AR-PD, Akinetic-rigid PD.
aPD subjects with no information on motor features available.
activity (Naylor and Clark, 1990; Delic et al., 1991) and that
causes differences in transcriptional activity of the promoter of
HMOX1 with different numbers of repeats. For the association
study of the HMOX1 GT(n), the alleles were divided into two
classes: class S including short repeat sequences (n < 25) and
class L including long repeat sequences (n ≥ 25) (Yamada
et al., 2000; Tiroch et al., 2007). The presence of this VNTR
polymorphism was analyzed after PCR amplification (forward
primer 5′-AGAGCCTGCAGCTTCTCAGA-3′ and reverse primer
5′-CTCTGGCTTCCTAGCAGGG-3′) and quantification of
number of repetitions by using GeneGel HyRes Denaturing gels,
and DNA staining kit Silver staining kit (GE Healthcare, Madrid,
Spain).
Three single nucleotide polymorphisms were studied bymeans
of TaqMan probes (Applied Biosciences Hispania, Alcobendas,
Madrid, Spain): The SNP rs2071746 (A/T) is an upstream vari-
ant located at 22:35380679, rs2071747 is a missense mutation
G/C (Asp/His) located at 22: 35381192, which corresponds to
exon 1 of the HMOX1 gene, and rs9282702 consists of a mis-
sense mutation C/T (Pro/Leu) located at 22:35386857, which
corresponds to exon 3 of the HMOX1 gene. Besides these SNPs,
no other non-synonymous HMOX1 SNPs have been reported
to occur in Caucasian individuals at frequencies over 1%.
Custom primers were designed to analyze the SNPs rs9282702
and rs2071747, whereas commercial primers were used for the
detection of the SNPs rs2071746 (C__15869717_10, Applied
Biosciences Hispania, Alcobendas, Madrid, Spain). The detection
was carried out by qPCR in an Eppendorf Realplex thermocycler
by using fluorescent probes. The amplification conditions were as
follows: After a denaturation time of 10min at 96◦C, 45 cycles
of 92◦C 15 s 60◦C 90 s were carried out and fluorescence was
measured at the end of each cycle and at endpoint. All samples
were determined in triplicate and genotypes were assigned both
by gene identification software (RealPlex 2.0, Eppendorf) and by
analysis of the reference cycle number for each fluorescence curve,
calculated by the CalQPlex algorithm (Eppendorf). For technical
validation purposes, the amplified fragments for 20 individu-
als carrying every genotype (AA, AT and TT for rs2071746 and
GG, GC and all carriers of the CC genotype for rs2071747 were
sequenced, and in all cases the genotypes fully corresponded with
those detected with fluorescent probes.
Copy number variations (CNVs) of the HMOX1 gene were
analyzed using the TaqMan copy number assay Hs00774483_cn
(Applied Biosciences Hispania), which was designed to hybridize
within the open reading frame in HMOX1 gene exon 3
(chromosome location 22:35782935). Amplification was carried
out in an Applied Biosystems 7500 real-time thermocycler as
described by the manufacturer, using as a copy number ref-
erence assay RNAse P. All reactions were carried out in qua-
druplicate. Results were analyzed by means of the CopyCaller
Software (Applied Biosciences Hispania). According to stan-
dard procedures in CNV analyses, we designed as heterozy-
gous (null/present) those samples with a single copy of the
HMOX1 gene.
STATISTICAL ANALYSIS
The Hardy–Weinberg equilibrium was analyzed with the
DeFinetti program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Allelic
and genotype analyses were performed with the PLINK software
(Purcell et al., 2007). Haplotype reconstruction was performed
using the program PHASE v2.1.1 (Stephens et al., 2001). This
reconstruction was carried out to detect putative association of
at risk haplotypes. We used the default model for recombination
rate variation with 1000 iterations, 500 burn-in iterations, and a
thinning interval of 1. Diplotypes were obtained from the com-
bination of haplotypes in the best run (the one that showed the
maximum consistency of results across all runs); further details
are provided elsewhere (Agundez et al., 2008b). Statistical analy-
ses were performed using the SPSS 15.0 for Windows (SPSS Inc.,
Chicago, Illinois, USA). Intergroup comparison values were cal-
culated by using the χ2 or Fisher tests when appropriate. The
95% confidence intervals were also calculated. The threshold
for statistical significance was p < 0.05. Correction for multiple
testing was done according the false discovery rate (FDR) pro-
cedure as described elsewhere (Benjamini and Hochberg, 1995).
The statistical power was determined from variant allele fre-
quencies observed in control individuals with a genetic model
analyzing the frequency for carriers of the disease gene with a
relative risk (RR) value = 1.5 (p = 0.05). The statistical power
for two-tailed associations for the presence of any of the two
SNPs identified in this study was 99.9% for overall patients with
PD, 98.3% for patients with C-PD and 95.4% for patients with
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an unknown PD phenotype. Testing for heterogeneous associa-
tion (homogeneity test) was analyzed by using the Breslow–Day
test.
RESULTS
At the first stage, because of DNA shortage, we analyzed the
occurrence of the four HMOX1 gene polymorphisms, including
the VNTR and the three SNPs described under methods, in 100
randomly selected samples from PD patients and 150 samples
from healthy individuals. The SNP rs9282702 was monomorphic.
The rest of gene variations analyzed were found to be polymor-
phic in the population study, and therefore we extended the
analyses to all patients and control individuals participating in
the study. CNV analyses in the whole study group revealed the
occurrence of three patients with PD and six control individu-
als with a single copy of the HMOX1 gene. All these individuals
were carriers of one null allele in heterozygosity. Individuals with
zero or more than two gene copies were not identified in the
study group. To our knowledge this is the first description of
the occurrence of CNVs in the HMOX1 gene, but the occur-
rence of CNVs does not seem to have a major association with
PD risk.
The combined genotypes obtained after SNP and CNV anal-
yses are summarized in Table 2. No deviation from Hardy–
Weinberg equilibrium was found for the SNPs or CNVs analyzed
either in the subgroups of patients suffering from PD or in the
control group. The risk of PD associated with the SNPs and
CNVs was estimated considering the major allele as the risk
allele, by comparison of allelic, heterozygous, and homozygous
dominant and recessive models. The major alleles for the SNPs
rs2071746 and rs2071747 were A and G, respectively, in agree-
ment with the allele frequencies shown in the 1000 genomes
catalog for European individuals (http://browser.1000genomes.
org/Homo_sapiens/Info/Index). The best fit was observed with
the dominant and the allelic models. We identified a statisti-
cally significant difference of the rs2071746 genotypes between
patients with C-PD and healthy individuals. This difference
was observed both in the dominant model and in the allelic
model. After correction for the three PD presentations (TD-
PD, C-PD, and AR-PD), these associations remained statistically
significant in the C-PD group. In addition, a weak statistically
significant difference in the frequency of HMOX1 rs2071746
genotypes between patients with TD-PD and healthy individu-
als was observed. This difference followed a dominant model,
but the difference was not statistically significant in the allelic
model (Table 2). When the 20 patients with C-PD and positive
family history of PD were excluded, the statistical significance
of the OR values were similar (not shown). No association
with the SNP rs2071747 was identified in any of the PD phe-
notypes. The SNPs, rs2071746, and rs2071747 did not show
linkage disequilibrium (D′ = 0.652, r = 0.147), and no par-
ticular risk haplotypes were identified in any of the study
groups.
As has been described previously, patients with the pheno-
types TP-PD and C-PD may have an earlier age at the onset than
the AR-PD group (Rajput et al., 2009), so we analyzed whether
HMOX1 rs2071746 genotype frequencies were related to age of Ta
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onset in the C-PD subgroup. Patients with C-PD phenotype were
subdivided according to the median age at onset in this subgroup
(62 years). Table 3 summarizes these results. We observed sta-
tistically significant differences among patients with early onset
of C-PD both, in the dominant model and in the allelic model,
whereas such significant differences were not observed among
patients with late-onset C-PD.
Regarding the HMOX-1 GT(n) polymorphism, we studied a
subset of the total of patients and healthy subjects included in
this study because of DNA shortage. Thus, 365 PD patients and
371 healthy subjects were genotyped. The number of repeats
ranged from 11 to 33, with the highest frequency for GT(20)
repeats in healthy subjects and GT(22) repeats in the case of PD
patients. Mann–Whitney comparison for means in each group
revealed statistically significant differences (p < 0.001). The asso-
ciation study of this polymorphism with PD patients is shown
Table 4.
DISCUSSION
BBB permeability is increased in the presence of reactive oxy-
gen species, and it is widely accepted that the HMOX1 mRNA
upregulation in CNS is a marker of oxidative stress. The enhanced
expression of HMOX1 may contribute to the pathological depo-
sition of iron which has been reported in normal aging CNS,
and to a much greater extent in neurodegenerative disorders
such as PD (Droge, 2002). Impaired HMOX1 activity caused by
genetic variants could modify the intraneuronal production of
biliverdin/bilirubin metabolites which exert an antioxidant role
(Dore et al., 1999) contributing to the etiology of PD and other
central nervous system disorders. Our group reported that func-
tional variations in HMOX2 gene are associated with PD risk
(Ayuso et al., 2011). In this context and bearing in mind that
HMOX1 has been postulated as a contributor to the pathological
iron deposition described in PD (Schipper et al., 2009), we aimed
to analyzed the possible role ofHMOX1 genetic variants in a large
series of PD patients.
We identified a clinical association of the HMOX1 rs2071746
polymorphism (A/T) with C-PD. The rs2071746 A allele was
more common among PD patients with C-PD phenotype than
in control individuals. Also, we observed that this association
was related with an early onset of the disease. In addition, the
analysis of the length of the highly polymorphic (GT)n dinu-
cleotide repeats indicates an association of longer (GT)n repeats
with susceptibility to PD. Both gene variations, rs2071746 and
(GT)n dinucleotide repeats sequence, have been related to varia-
tions in the transcriptional activity of the HMOX1 gene (Yamada
et al., 2000; Tanaka et al., 2011; Kramer et al., 2013). According
published evidence, the number of (GT)n repeats inversely cor-
relates with HMOX1 promoter activity and inducibility of the
gene (Yamada et al., 2000), although controversy exist (Tanaka
et al., 2011). It has been shown that the rs2071746 A allele is
associated with high promoter activity (Ono et al., 2004). Our
findings support an increased frequency of carriers of long (≥25
(GT)n) among PD patients and an increased frequency of carri-
ers of the rs2071746 A allele among PD patients. Although these
findings apparently point to opposite directions in terms of gene
activity, the functional effect of these polymorphisms is not fully Ta
b
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Table 4 | Genotype and allele frequencies for (GT)n repeat polymorphisms in PD patients and healthy subjects.
Patients Genotype frequencies (%) P (dominant model) OR (95% CI) Allele frequencies (%) P (allelic model) OR (95%CI)
S/S S/L L/L S L
PD (N = 365) 86.3 12.3 1.4 0.0001 0.34 (0.20–0.59) 0.92 0.08 0.0001 0.37 (0.23–0.62)
Controls (N = 371) 94.9 4.3 0.8 0.97 0.03 Ref
S, short repeat sequences (n < 25 (GT)n); L long repeats sequences (n ≥ 25 (GT)n).
understood. Moreover, an extended model of the HMOX1 gene
along with the importance of alternative splicing in the area where
these two polymorphisms are located, and its association with
translational regulation has been disclosed recently (Kramer et al.,
2013).
Our results agree with those by Kimpara et al. (1997) although
other studies that failed to confirm these findings have been pub-
lished (Funke et al., 2009). Putative discrepancy in the genetic
associations may be explained because of the different ethnic ori-
gin of the participants included in each of these studies. Infante
et al. (2010) reported association of the rs2071746 T allele in
homozygosity as a risk factor for PD, but only when combined
with another SNPs at the GSK3beta gene, and in a relatively small
study group. In the study by Infante et al. however the rs2071746
T allele frequency is almost identical in patients and controls (39
and 37%). In fact, when the comparison of the rs2071746 geno-
types or allele frequencies between patients and controls is made,
no statistically significant differences are observed (Infante et al.,
2010). In our study the association is statistically significant when
analyzing genotypes or allele frequencies. Moreover, the large
sample size analyzed in the present study and the fact that positive
associations remained statistically significant after correction for
multiple testing support the observed genetic associations. The
effect of the rs2071746 SNP on different PD subgroups seems pre-
senting consistent patterns, though some did not pass significance
threshold. In fact, taking into consideration the dominant model
(Table 2) the findings obtained in TD-PD and C-PD patients
show different directions. Nevertheless it should be considered
that the subgroup of TD-PD is composed of 30 patients only.
These apparent discrepancies, and the lack of statistical signif-
icance in some subgroups, may be related to the small sample
size of some of these subgroups. In addition, we analyzed for
the first time the occurrence of CNVs in HMOX1, both in PD
patients and in healthy individuals. We found CNVs more fre-
quently in AR-PD patients. Although this study does not support
a major role of HMOX1 CNVs in PD risk, the demonstration
of the occurrence of CNVs in the HMOX1 gene supports fur-
ther research in the functional role and clinical associations of
HMOX1 CNVs. It is of note, however, that the association can-
not be observed in the subgroup of PD patients with unknown
phenotype. Our findings suggest that the association of HMOX1
genotypes and PD risk is specific of the C-PD phenotype. This
reinforces the need of detailed phenotyping and categorization of
patients in genetic association studies, particularly when assessing
low-penetrance factors. In summary, in this study we identi-
fied two functional HMOX1 gene variations as potential genetic
biomarkers of PD. It is conceivable that these genetic biomarkers
would be associated to other disorders related to oxidative stress
in the CNS and in the BBB. This study adds to current knowledge
of genetic biomarkers in PD (Alonso-Navarro et al., 2014) and
other CNS disorders (Agundez et al., 2013) and, once these
biomarkers are validated, these could be used to identify at risk
individuals and to provide proof of concept regarding the mech-
anisms involved in the development of these diseases. Further
research would be needed to analyze HMOX1 genetic variations
in an independent population to verify these associations and
to analyze putative interethnic variability in the observed genetic
association.
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